CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients

A unique subset of NK cells possibly associated with graft-versus-leukemia effect

Xuzhang Lu, Yukio Kondo, Hiroyuki Takamatsu, Kinya Ohata, Hirohito Yamazaki, Akiyoshi Takami, Yoshiki Akatsuka, Shinji Nakao

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

A marked increase in CD16+ CD56- NK cells in the peripheral blood (PB) was observed in a cord blood transplant (CBT) recipient with refractory acute myeloid leukaemia (AML) in association with attaining molecular remission. CD16+ CD56- NK cells isolated from the patient became CD16+CD56+NKG2D+ when they were cultured in the presence of IL-2. Although cultured CD16 +CD56- NK cells retained the killer-cell immunoglobulin receptor (KIR)-ligand (KIR-L) specificity and the patient's leukemic cells expressed corresponding KIR ligands, they killed patient's leukemic cells expressing ULBP2. The cytotoxicity by cultured CD16+CD56- NK cells was abrogated by anti-ULBP2 antibodies. When leukemic cells obtained at relapse after CBT were examined, both the ULBP2 expression and susceptibility to the cultured NK cells decreased in comparison to leukemic cells obtained before CBT. An increase in the CD16+CD56- NK cell count (0.5 × 109/L or more) in PB was observed in seven of 11 (64%) CBT recipients but in none of 13 bone marrow (BM) and eight peripheral blood stem cell (PBSC) transplant recipients examined during the similar period after transplantation. These findings suggest an increase in CD16+CD56 - NK cells to be a phenomenon unique to CBT recipients and that mature NK cells derived from this NK cell subset may contribute to the killing of leukemic cells expressing NKG2D ligands in vivo.

Original languageEnglish
Pages (from-to)18-25
Number of pages8
JournalEuropean Journal of Haematology
Volume81
Issue number1
DOIs
Publication statusPublished - 01-07-2008
Externally publishedYes

Fingerprint

Fetal Blood
Natural Killer Cells
Leukemia
Transplants
Ligands
Immunoglobulins
Transplant Recipients
Acute Myeloid Leukemia
Interleukin-2
Anti-Idiotypic Antibodies
Cultured Cells
Cell Count
Transplantation
Bone Marrow
Recurrence

All Science Journal Classification (ASJC) codes

  • Hematology

Cite this

Lu, Xuzhang ; Kondo, Yukio ; Takamatsu, Hiroyuki ; Ohata, Kinya ; Yamazaki, Hirohito ; Takami, Akiyoshi ; Akatsuka, Yoshiki ; Nakao, Shinji. / CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients : A unique subset of NK cells possibly associated with graft-versus-leukemia effect. In: European Journal of Haematology. 2008 ; Vol. 81, No. 1. pp. 18-25.
@article{898e04e594754078b6b9d87ce6293626,
title = "CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients: A unique subset of NK cells possibly associated with graft-versus-leukemia effect",
abstract = "A marked increase in CD16+ CD56- NK cells in the peripheral blood (PB) was observed in a cord blood transplant (CBT) recipient with refractory acute myeloid leukaemia (AML) in association with attaining molecular remission. CD16+ CD56- NK cells isolated from the patient became CD16+CD56+NKG2D+ when they were cultured in the presence of IL-2. Although cultured CD16 +CD56- NK cells retained the killer-cell immunoglobulin receptor (KIR)-ligand (KIR-L) specificity and the patient's leukemic cells expressed corresponding KIR ligands, they killed patient's leukemic cells expressing ULBP2. The cytotoxicity by cultured CD16+CD56- NK cells was abrogated by anti-ULBP2 antibodies. When leukemic cells obtained at relapse after CBT were examined, both the ULBP2 expression and susceptibility to the cultured NK cells decreased in comparison to leukemic cells obtained before CBT. An increase in the CD16+CD56- NK cell count (0.5 × 109/L or more) in PB was observed in seven of 11 (64{\%}) CBT recipients but in none of 13 bone marrow (BM) and eight peripheral blood stem cell (PBSC) transplant recipients examined during the similar period after transplantation. These findings suggest an increase in CD16+CD56 - NK cells to be a phenomenon unique to CBT recipients and that mature NK cells derived from this NK cell subset may contribute to the killing of leukemic cells expressing NKG2D ligands in vivo.",
author = "Xuzhang Lu and Yukio Kondo and Hiroyuki Takamatsu and Kinya Ohata and Hirohito Yamazaki and Akiyoshi Takami and Yoshiki Akatsuka and Shinji Nakao",
year = "2008",
month = "7",
day = "1",
doi = "10.1111/j.1600-0609.2008.01073.x",
language = "English",
volume = "81",
pages = "18--25",
journal = "European Journal of Haematology",
issn = "0902-4441",
publisher = "Wiley-Blackwell",
number = "1",

}

CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients : A unique subset of NK cells possibly associated with graft-versus-leukemia effect. / Lu, Xuzhang; Kondo, Yukio; Takamatsu, Hiroyuki; Ohata, Kinya; Yamazaki, Hirohito; Takami, Akiyoshi; Akatsuka, Yoshiki; Nakao, Shinji.

In: European Journal of Haematology, Vol. 81, No. 1, 01.07.2008, p. 18-25.

Research output: Contribution to journalArticle

TY - JOUR

T1 - CD16+ CD56- NK cells in the peripheral blood of cord blood transplant recipients

T2 - A unique subset of NK cells possibly associated with graft-versus-leukemia effect

AU - Lu, Xuzhang

AU - Kondo, Yukio

AU - Takamatsu, Hiroyuki

AU - Ohata, Kinya

AU - Yamazaki, Hirohito

AU - Takami, Akiyoshi

AU - Akatsuka, Yoshiki

AU - Nakao, Shinji

PY - 2008/7/1

Y1 - 2008/7/1

N2 - A marked increase in CD16+ CD56- NK cells in the peripheral blood (PB) was observed in a cord blood transplant (CBT) recipient with refractory acute myeloid leukaemia (AML) in association with attaining molecular remission. CD16+ CD56- NK cells isolated from the patient became CD16+CD56+NKG2D+ when they were cultured in the presence of IL-2. Although cultured CD16 +CD56- NK cells retained the killer-cell immunoglobulin receptor (KIR)-ligand (KIR-L) specificity and the patient's leukemic cells expressed corresponding KIR ligands, they killed patient's leukemic cells expressing ULBP2. The cytotoxicity by cultured CD16+CD56- NK cells was abrogated by anti-ULBP2 antibodies. When leukemic cells obtained at relapse after CBT were examined, both the ULBP2 expression and susceptibility to the cultured NK cells decreased in comparison to leukemic cells obtained before CBT. An increase in the CD16+CD56- NK cell count (0.5 × 109/L or more) in PB was observed in seven of 11 (64%) CBT recipients but in none of 13 bone marrow (BM) and eight peripheral blood stem cell (PBSC) transplant recipients examined during the similar period after transplantation. These findings suggest an increase in CD16+CD56 - NK cells to be a phenomenon unique to CBT recipients and that mature NK cells derived from this NK cell subset may contribute to the killing of leukemic cells expressing NKG2D ligands in vivo.

AB - A marked increase in CD16+ CD56- NK cells in the peripheral blood (PB) was observed in a cord blood transplant (CBT) recipient with refractory acute myeloid leukaemia (AML) in association with attaining molecular remission. CD16+ CD56- NK cells isolated from the patient became CD16+CD56+NKG2D+ when they were cultured in the presence of IL-2. Although cultured CD16 +CD56- NK cells retained the killer-cell immunoglobulin receptor (KIR)-ligand (KIR-L) specificity and the patient's leukemic cells expressed corresponding KIR ligands, they killed patient's leukemic cells expressing ULBP2. The cytotoxicity by cultured CD16+CD56- NK cells was abrogated by anti-ULBP2 antibodies. When leukemic cells obtained at relapse after CBT were examined, both the ULBP2 expression and susceptibility to the cultured NK cells decreased in comparison to leukemic cells obtained before CBT. An increase in the CD16+CD56- NK cell count (0.5 × 109/L or more) in PB was observed in seven of 11 (64%) CBT recipients but in none of 13 bone marrow (BM) and eight peripheral blood stem cell (PBSC) transplant recipients examined during the similar period after transplantation. These findings suggest an increase in CD16+CD56 - NK cells to be a phenomenon unique to CBT recipients and that mature NK cells derived from this NK cell subset may contribute to the killing of leukemic cells expressing NKG2D ligands in vivo.

UR - http://www.scopus.com/inward/record.url?scp=45449120864&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=45449120864&partnerID=8YFLogxK

U2 - 10.1111/j.1600-0609.2008.01073.x

DO - 10.1111/j.1600-0609.2008.01073.x

M3 - Article

VL - 81

SP - 18

EP - 25

JO - European Journal of Haematology

JF - European Journal of Haematology

SN - 0902-4441

IS - 1

ER -